| 臺大學術典藏 |
2022-06-27T07:07:47Z |
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer
|
Mok T.S.K.; Wu Y.-L.; CHONG-JEN YU; Zhou C.; Chen Y.-M.; Zhang L.; Ignacio J.; Liao M.; Srimuninnimit V.; Boyer M.J.; Chua-Tan M.; Sriuranpong V.; Sudoyo A.W.; Jin K.; Johnston M.; Chui W.; Lee J.-S. |
| 臺大學術典藏 |
2022-06-27T07:02:01Z |
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial
|
Wu Y.-L.; Lee J.S.; Thongprasert S.; CHONG-JEN YU; Zhang L.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; Sandoval-Tan J.; Zhu Y.; Liao M.; Zhou C.; Pan H.; Lee V.; Chen Y.-M.; Sun Y.; Margono B.; Fuerte F.; Chang G.-C.; Seetalarom K.; Wang J.; Cheng A.; Syahruddin E.; Qian X.; Ho J.; Kurnianda J.; Liu H.E.; Jin K.; Truman M.; Bara I.; Mok T. |
| 臺大學術典藏 |
2022-06-27T07:01:34Z |
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
|
Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. |
| 臺大學術典藏 |
2022-06-27T07:00:18Z |
Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer
|
Mok T.; Ladrera G.; Srimuninnimit V.; Sriuranpong V.; CHONG-JEN YU; Thongprasert S.; Sandoval-Tan J.; Lee J.S.; Fuerte F.; Shames D.S.; Klughammer B.; Truman M.; Perez-Moreno P.; Wu Y.-L. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2021-01-28T01:06:23Z |
Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study
|
Cheng A.-L.;Cornelio G.;Shen L.;Price T.;Yang T.-S.;Chung I.J.;Dai G.-H.;Lin J.-K.;Sharma A.;Kun-Huei Yeh;Ma B.;Zaatar A.;Guan Z.;Masood N.;Srimuninnimit V.;Yau T.;Gibbs P.;Wang X.;Doval D.C.;Oh S.-T.;Shim B.Y.;Gorospe C.;Wang H.-M.;Sirachainan E.;Hill A.;Suh K.W.;Beier F.;Chatterjee S.;Lim R.; Cheng A.-L.; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; KUN-HUEI YEH; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R. |
| 臺大學術典藏 |
2020-08-12T06:34:46Z |
Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC Patients treated with first-line intercalated erlotinib and chemotherapy
|
Mok T.;Wu Y.-L.;Lee J.S.;Chong-Jen Yu;Sriuranpong V.;Sandoval-Tan J.;Ladrera G.;Thongprasert S.;Srimuninnimit V.;Liao M.;Zhu Y.;Zhou C.;Fuerte F.;Margono B.;Wen W.;Tsai J.;Truman M.;Klughammer B.;Shames D.S.;Wu L.; Mok T.; Wu Y.-L.; Lee J.S.; CHONG-JEN YU; Sriuranpong V.; Sandoval-Tan J.; Ladrera G.; Thongprasert S.; Srimuninnimit V.; Liao M.; Zhu Y.; Zhou C.; Fuerte F.; Margono B.; Wen W.; Tsai J.; Truman M.; Klughammer B.; Shames D.S.; Wu L. |
| 臺大學術典藏 |
2020-05-26T09:26:59Z |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: A randomised, phase 3 trial
|
CHIH-HSIN YANG; Kang J.H; Mok T; Ahn M.-J; Srimuninnimit V; Lin C.-C; Kim D.-W; Tsai C.-M; Barraclough H; Altug S; Orlando M; Park K. |
| 臺大學術典藏 |
2020-05-26T09:26:49Z |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial
|
Chih-Hsin Yang;Rajan N;Kim J.S;Puri T;Orlando M;Tsai C.-M;Kang J.H;Srimuninnimit V;Wang X;Boye M; Boye M; Wang X; Srimuninnimit V; Kang J.H; Tsai C.-M; Orlando M; Puri T; Kim J.S; Rajan N; CHIH-HSIN YANG |
| 臺大學術典藏 |
2020-05-26T09:26:48Z |
Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study
|
Park K.;Wang X;Puri T;Orlando M;Mok T;Tsai C.-M;Kim S.-W;Lin C.-C;Ahn M.-J;Srimuninnimit V;Chih-Hsin Yang; CHIH-HSIN YANG; Srimuninnimit V; Ahn M.-J; Lin C.-C; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. |
